Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients

American Heart Journal

Volumn 152, Issue 2, 2006, Pages 312-320

  Collins, Richard P ^a   Palmer, Barry R ^a   Pilbrow, Anna P ^a   Frampton, Chris M ^a   Troughton, Richard W ^a   Yandle, Tim G ^a   Skelton, Lorraine ^a   Richards, A Mark ^a   Cameron, Vicky A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE MONOPHOSPHATE DEAMINASE; NEUROHORMONE;

ADULT; AGED; ALLELE; ANAMNESIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA POLYMORPHISM; ECHOCARDIOGRAPHY; FEMALE; GENE MUTATION; GENETIC RISK; GENOTYPE; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART VENTRICULOGRAPHY; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; SURVIVAL;

AGED; ALDOSTERONE; AMP DEAMINASE; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; ENDOTHELIN-1; EPINEPHRINE; FEMALE; GENOTYPE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; NOREPINEPHRINE; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 33746218164     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.12.015     Document Type: Article

References (33)

1. Morisaki T., Gross M., Morisaki H., et al. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci U S A 89 (1992) 6457-6461
2. Flanagan W.F., Holmes E.W., Sabina R.L., et al. Importance of purine nucleotide cycle to energy production in skeletal muscle. Am J Physiol 251 (1986) C795-C802
3. Morisaki H., Morisaki T., Newby L.K., et al. Alternative splicing: a mechanism for phenotypic rescue of a common inherited defect. J Clin Invest 91 (1993) 2275-2280
4. Kalsi K.K., Yuen A.H., Rybakowska I.M., et al. Decreased cardiac activity of AMP deaminase in subjects with the AMPD1 mutation-a potential mechanism of protection in heart failure. Cardiovasc Res 59 (2003) 678-684
5. Sabina R.L., Swain J.L., Olanow C.W., et al. Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. J Clin Invest 73 (1984) 720-730
6. Villarreal F., Zimmermann S., Makhsudova L., et al. Modulation of cardiac remodeling by adenosine: in vitro and in vivo effects. Mol Cell Biochem 251 (2003) 17-26
7. Funaya H., Kitakaze M., Node K., et al. Plasma adenosine levels increase in patients with chronic heart failure. Circulation 95 (1997) 1363-1365
8. Loh E., Rebbeck T.R., Mahoney P.D., et al. Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation 99 (1999) 1422-1425
9. Anderson J.L., Habashi J., Carlquist J.F., et al. A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease. J Am Coll Cardiol 36 (2000) 1248-1252
10. Yazaki Y., Muhlestein J.B., Carlquist J.F., et al. A common variant of the AMPD1 gene predicts improved survival in patients with ischemic left ventricular dysfunction. J Card Fail 10 (2004) 316-320
11. Gastmann A., Sigusch H.H., Henke A., et al. Role of adenosine monophosphate deaminase-1 gene polymorphism in patients with congestive heart failure (influence on tumor necrosis factor-alpha level and outcome). Am J Cardiol 93 (2004) 1260-1264
12. Andreassi M.G., Botto N., Laghi-Pasini F., et al. AMPD1 (C34T) polymorphism and clinical outcomes in patients undergoing myocardial revascularization. Int J Cardiol 101 (2005) 191-195
13. McKee P.A., Castelli W.P., McNamara P.M., et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med 285 (1971) 1441-1446
14. Richards A., Nicholls M., Yandle T., et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. Heart 81 (1999) 114-120
15. Palmer B., Pilbrow A., Frampton C., et al. ACE gene polymorphism interacts with LVEF and BNP levels to predict mortality following myocardial infarction. J Am Coll Cardiol 41 (2003) 729-736
16. Richards A.M., Nicholls M.G., Espiner E.A., et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107 (2003) 2786-2792
17. Gross M. New method for detection of C34-T mutation in the AMPD1 gene causing myoadenylate deaminase deficiency. Ann Rheum Dis 53 (1994) 353-354
18. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
19. Gustafsson F., Torp-Pedersen C., Seibaek M., et al. Effect of age on short and long-term mortality in patients admitted to hospital with congestive heart failure. Eur Heart J 25 (2004) 1711-1717
20. De Groote P., Lamblin N., Mouquet F., et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J 25 (2004) 656-662
21. Bohm M., and Maack C. Treatment of heart failure with beta-blockers. Mechanisms and results. Basic Res Cardiol 95 Suppl 1 (2000) I15-I24
22. Hillege H.L., Girbes A.R., de Kam P.J., et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102 (2000) 203-210
23. Tsutamoto T., Wada A., Maeda K., et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 20 (1999) 1799-1807
24. Gardner R.S., Ozalp F., Murday A.J., et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24 (2003) 1735-1743
25. Michaels A.D., and Goldschlager N. Risk stratification after acute myocardial infarction in the reperfusion era. Prog Cardiovasc Dis 42 (2000) 273-309
26. Gundersen T., Grottum P., Pedersen T., et al. Effect of timolol on mortality and reinfarction after acute myocardial infarction: prognostic importance of heart rate at rest. Am J Cardiol 58 (1986) 20-24
27. de Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 (2001) 1014-1021
28. Mahaffey K.W., Puma J.A., Barbagelata N.A., et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 34 (1999) 1711-1720
29. Camaiti A., Pieralli F., Olivotto I., et al. Prospective evaluation of adenosine-induced proarrhythmia in the emergency room. Eur J Emerg Med 8 (2001) 99-105
30. Mullane K., and Bullough D. Harnessing an endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine. J Mol Cell Cardiol 27 (1995) 1041-1054
31. Modlinger P.S., and Welch W.J. Adenosine A1 receptor antagonists and the kidney. Curr Opin Nephrol Hypertens 12 (2003) 497-502
32. Gottlieb S.S., Brater D.C., Thomas I., et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105 (2002) 1348-1353
33. Ben-Sorek E.S., and Wiesel J. Ventricular fibrillation following adenosine administration. A case report. Arch Intern Med 153 (1993) 2701-2702